Key Highlights

  • Digital mental health has been a volatile place to invest, and Kooth (AIM: KOO) has embodied both the promise and the pitfalls.
  • For the 2025 full year, Revenue was £63.3m with adjusted EBITDA of £11.3m and pre-tax profit of £4.4m.
  • The Soluna programme in California, which entered its fourth year in 2026, had drawn more than 187,000 registrations by mid-year.
  • The renewed interest is grounded in a sharply improved Earnings profile, a strong net-cash position and a Business diversifying beyond a single contract.

Digital mental health has been a volatile place to invest, and Kooth (LSE: KOO) has embodied both the promise and the pitfalls. The company provides anonymous online mental-health support in the UK and, through its Soluna app, to young people across California under a landmark state contract. While there is no confirmed evidence of a recent, dated share-price surge, an encouraging summer trading update has given investors fresh reason to reassess the stock.

Latest Company Development

In a half-year trading update on 29 July 2026, Kooth pointed to a marked improvement in profitability. Adjusted EBITDA for the first half was guided to roughly £5.0m--£5.4m, up from £1.6m a year earlier, even as revenue eased to £30.8m on planned tapering of Californian product-development income and adverse currency movements. Net cash rose to £23.1m, and the company remains debt-free. Kooth is also broadening its footprint, with a renewed New Jersey contract, a Michigan win worth around $2.6m, a US telehealth platform acquisition, and a planned UK launch of Soluna in the second half of 2026. It is worth noting a common point of confusion: under California's youth mental-health initiative, Soluna is Kooth's product for those aged 13 to 25, whereas the separately branded BrightLife Kids service for younger children is run by a different company.

The Financial and Operational Picture

For the 2025 full year, revenue was £63.3m with adjusted EBITDA of £11.3m and pre-tax profit of £4.4m. The Soluna programme in California, which entered its fourth year in 2026, had drawn more than 187,000 registrations by mid-year. The flip side is currency exposure: a large share of revenue is US-dollar denominated, which has repeatedly swung reported results.

Why Investors Are Watching

The renewed interest is grounded in a sharply improved earnings profile, a strong net-cash position and a business diversifying beyond a single contract. For investors who had written off the sector after earlier disappointments, a tripling of first-half EBITDA is a genuine reason to look again.

The Investment Case

Kooth combines a defensible UK public-sector Franchise — commissioned by the NHS, local authorities and schools — with a proven US delivery model and a debt-free balance sheet. New state contracts and the UK Soluna launch offer growth optionality, while the improved margins suggest the model can be run profitably. Under chief executive Kate Newhouse, who succeeded long-standing boss Tim Barker, the company says it now provides access to mental-health support to more than 20 million people across the US and UK. It is worth separating this operational progress from any assumption about short-term share-price direction.

Risks

The central risk is concentration. Kooth's largest single revenue source is its Californian contract, leaving it exposed to state-budget cycles and renewal decisions. Heavy US-dollar revenue makes results sensitive to sterling strength, as recent periods have shown. Public-sector procurement can be slow and lumpy, and as an AIM stock Liquidity is limited.

What Comes Next

Full half-year results are due in September 2026 and will confirm the trading-update figures. Beyond that, the UK launch of Soluna, progress on the Michigan and New Jersey contracts, and any signals on the Californian renewal are the developments most likely to shape sentiment.

Outlook

Kooth's summer update suggests the operational picture is improving materially, with earnings and cash both moving in the right direction and the customer base widening. That is a more solid foundation than the sector has often offered. Investors should nonetheless keep the risks in view: contract concentration and currency exposure remain the swing factors, and there is no verified evidence of a recent share-price jump to chase. The stronger case here is fundamental progress rather than momentum, and the September results will be the next real test.